On June 1st, the innovative drug sector surged strongly, with AKESO rising over 10%, 3SBio rising over 6%, and WuXi AppTec rising over 5%.
The GF CSI HK Innovative Drugs Industry ETF (abbreviated as: HK Innovative Drugs ETF GF, fund code 513120) tracking the HK Innovative Drugs Index, rose nearly 3%.
At the 2026 &#34;Global Top Oncology Conference&#34; ASCO, AKESO announced the overall survival (OS) results of the HARMONi-6 study for first-line treatment of advanced squamous NSCLC with Ivosidenib combined with chemotherapy, which enrolled a total of 532 patients. The Ivosidenib + chemotherapy group showed significant OS benefits compared to the Tislelizumab + chemotherapy group.
The head-to-head PD-1 monoclonal antibody achieved superior OS, further validating the value of the dual antibody mechanism. With a median follow-up of 21.4 months, the mOS in the Ivosidenib group reached 27.9 months, compared to 23.7 months in the control group, with a 34% reduction in the risk of death (HR=0.66, 95%CI 0.50-0.87, P=0.0017, less than the threshold of 0.0049), reaching the pre-set statistical significance boundary. The 24-month OS rates were 64.7% vs 48.6%, with survival curves continuing to separate, showing a clear trend of long-term benefit.
Insiders stated that this research result, with robust Phase III head-to-head clinical research data, redefines the gold standard for first-line treatment of sq-NSCLC and establishes a new benchmark for clinical benefits, marking a milestone in China's innovation driving the improvement of global cancer treatment levels.
AKESO's 2024 performance materials cited a report from Goldman Sachs Global Investment Research dated February 28, 2025, stating that the potential global peak sales of Ivosidenib could reach $53 billion.
In addition, at the 2026 ASCO conference, domestic innovative drugs occupied the center stage of academia with multiple breakthrough studies, achieving a leap from &#34;quantity breakthrough&#34; to &#34;quality leadership.&#34; According to statistics from YaoYuan, 13 studies from 12 Chinese innovative drug companies were selected for the most significant plenary sessions and latest breakthrough abstracts (LBA), setting a historical high. Based on the disclosed abstracts, domestic innovative drugs cover mainstream and cutting-edge molecular forms such as monoclonal antibodies, dual antibodies, multi-antibodies, ADCs, and dual-antibody ADCs, achieving breakthroughs in multiple fields including lung cancer, breast cancer, and gastrointestinal tumors.
Century Securities' research report pointed out that this conference showcased a distinct characteristic of simultaneous quantity and quality improvement among Chinese innovative drug companies, with 13 Chinese studies selected for the latest breakthrough abstracts (LBA), setting a historical high; 94 Chinese studies selected for oral presentations, covering various drug types such as dual antibodies, ADCs, TCEs, and multiple cancer types including lung cancer, breast cancer, and gastrointestinal tumors. This series of data releases marks that Chinese innovative drugs are moving towards global source innovation, at a juncture where the global cancer treatment paradigm is transitioning from the era of monoclonal antibodies + chemotherapy to the iteration of second-generation IO dual antibodies/ADCs combined therapy, with domestic innovative drugs gaining recognition from MNCs due to their differentiated platform capabilities
As of 9:37, the Hong Kong Innovative Drug ETF by GF (513120) rose over 1% during the session; among the top ten weighted stocks, Innovent Biologics rose 0.3%, AKESO rose 9.23%, BeiGene rose 0.9%, WuXi Biologics rose 5.4%, CSPC Pharmaceutical Group rose 3.33%, China National Pharmaceutical Group rose 2.4%, Hansoh Pharmaceutical rose 2.23%, WuXi AppTec rose 1.53%, 3SBio rose 6.92%, and Crystal International Holdings rose 1.21%.
The fund continues to receive inflows. As of the previous trading day, the fund had a net inflow of CNY 675 million over the past month, a net inflow of CNY 1.319 billion over the past three months, a net inflow of CNY 3.059 billion over the past six months, and a net inflow of CNY 15.434 billion over the past year.
It is noteworthy that the Hong Kong Innovative Drug ETF by GF (513120) is currently the only ETF tracking the Hong Kong Innovative Drug Index in the entire market, making it scarce. The fund supports T+0 trading, allowing investors to quickly respond to market fluctuations and flexibly allocate funds for efficient capital utilization.
Investors can easily access the GF CSI HK Innovative Drugs Industry ETF (on-market abbreviation: Hong Kong Innovative Drug ETF by GF, fund code 513120), while off-market investors can participate through Off-Market Link A (019670) and Off-Market Link C (019671).
In addition to the Hong Kong Innovative Drug ETF by GF (513120), GF Fund has also launched several products in various pharmaceutical sub-sectors to meet different investment needs:
Hang Seng Biotechnology ETF by GF (159169): Focuses on the Hong Kong biotechnology sector, covering high-growth areas such as innovative drugs, vaccines, and gene therapy.
Innovative Drug ETF by GF (515120): Invests in the A-share innovative drug industry chain, balancing large and small market cap targets to share in the domestic innovation dividend

09926

513060

516930

At the 2026 ASCO Annual Meeting, AKESO announced overall survival data from the HARMONi-6 study on the combination of Ivosidenib and chemotherapy for advanced squamous NSCLC, showing a 34% reduction in the risk of death, establishing a new clinical benchmark. Due to this positive news and several breakthroughs in domestic innovative drugs, the innovative drug sector surged strongly on June 1, with the Hong Kong innovative drug ETF GF rising nearly 3%

同壁财经

AKESO

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua SSE STAR Biology and Medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Huaan Hang Seng Biotech ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

3SBIO

WUXI BIO

Goldman Sachs

INNOVENT BIO

BEONE MEDICINES

Beigene

BeOne Medicines

CSPC PHARMA

SBP GROUP

HANSOH PHARMA

WUXI APPTEC

WuXi AppTec

XTALPI

GF Fund Hang Seng Biotech ETF

GF CSI Innovative Drugs Industry ETF

Sunshine Guojian Pharmaceutical

WuXi Biologics

GS Hldg R

Chinese innovative drugs shine at the 2026 ASCO! AKESO's combination chemotherapy with Yvoxi reduces the risk of patient death by 34%! The Hong Kong innovative drug ETF GF (513120) rose nearly 3% during trading, with AKESO's weight in the underlying index exceeding 9%